Could a targeted immune blocker tame a deadly heart side effect of cancer drugs?
NCT ID NCT05195645
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the drug abatacept can safely and effectively treat severe heart inflammation (myocarditis) caused by immune checkpoint inhibitors, a type of cancer immunotherapy. The study enrolls adults with any cancer who develop this rare but often fatal heart complication. Researchers will test three different doses of abatacept to find the lowest dose that adequately blocks a specific immune signal, aiming to calm the overactive immune response without harming the anti-cancer effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- abatacept (also known as Orencia), given by intravenous injection
- What this could lead to
- If successful, this could provide a targeted treatment for a rare but often fatal heart complication from cancer immunotherapy, potentially saving lives.
- What could go wrong
- This is a small, early-phase dose-finding trial with only 21 participants, so results may not apply broadly. Abatacept also suppresses the immune system, which could reduce the anti-cancer effect of the immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Pitié Salpêtrière
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could spot hidden heart inflammation
- 5,000 patients to help unlock secrets of inflammatory heart disease
- New MRI scan could spot heart problems earlier
- Old gout drug may tame deadly heart inflammation
- Heart disease detective: 1,000-Person study hunts for hidden genetic triggers of sudden cardiac death
- Three extra minutes on an MRI could catch a deadly side effect of cancer treatment